Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs
This article was originally published in The Pink Sheet Daily
Executive Summary
Rx products which could have implications for OTC markets include Schering-Merck’s Claritin/Singulair combination and new Schering Clarinex formulations. Pfizer’s nicotine replacement therapy varenicline is in Phase III; Relpax and Celebrex gain market share in migraine, arthritis markets, respectively.
You may also be interested in...
Pfizer Has 41% Of Arthritis Market Post-Vioxx
Pfizer and FDA have agreed to "black box" for Bextra skin reactions and will address safety in post-op patients "separately" in new labeling. Pfizer plans NDA for parecoxib by the end of the year.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.